FDA limits monoclonal antibody treatments shown to be ineffective against omicron

The Food and Drug Administration revised authorization of two types of monoclonal antibody treatments for COVID-19 due to growing evidence they do not fight infection of the omicron variant, which accounts for the vast majority of new infections in the United States.

“Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research.